ClinicalTrials.gg
RecruitingNCT06455319Updated Nov 16, 2026

Precision Administration of Anti-thymocyte Globulin With or Without Verapamil

A Phase 2 interventional study of Anti-thymocyte globulin (ATG) and verapamil extended release capsule in Type 1 Diabetes, sponsored by University of Florida. Recruiting at 2 sites in United States. Open to participants aged 4 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by University of Florida · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Nov 16, 2026Eligibility revisedPrimary outcomes revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
4 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies testing Antilymphocyte Serum in Diabetes Mellitus, Type 1 — 2 open to participants now, 2 under way, none of them phase 3. Antilymphocyte Serum · Diabetes Mellitus, Type 1.

Planned enrollment
3rd of 12
60 · median 36
Started
2025
the only one that year
Phase 2
7 of 12
2 open now
Registered
11th of 12
by date
Lead sponsor
1 of 12
University of Florida

Among the 12 studies testing Antilymphocyte Serum in Diabetes Mellitus, Type 1, this one is the 3rd largest by planned enrollment, is the only one that started in 2025, is one of 7 in phase 2, and was the 11th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 12 studies testing Antilymphocyte Serum in Diabetes Mellitus, Type 1 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About Antilymphocyte Serum

Antilymphocyte Serum: first FDA approval 1996 (Atgam). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 4 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing Antilymphocyte Serum in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

T cell directed therapy, anti-thymocyte globulin (ATG), in low doses, has been shown to lower HbA1c and preserve endogenous insulin production (measured by C-peptide) in individuals with recently diagnosed type 1 diabetes (T1D). However, not all individuals who received ATG responded to the therapy (i.e., non-responders). Additionally, use of ATG alone does not address inherent beta cell stress. A calcium channel blocker, verapamil, has demonstrated C-peptide preservation in newly diagnosed T1D. Investigators will identify those mostly likely to respond to ATG using an ex vivo predictive biomarker of response to ATG. In addition, Investigators will use sequential therapies to increase efficacy (ATG followed by verapamil) and explore synergistic mechanisms. This will be assessing with in depth immunophenotyping and quantify biomarkers of beta cell stress, cell death, and abnormal prohormone processing. Finally, novel clinical trial endpoints will be assessed for their ability to predict treatment efficacy earlier than the standard endpoint at 1 year.

Read the detailed description

Investigators will conduct a multi-center, open label clinical trial testing low-dose ATG in pre-stratified ATG responders and non-responders (and pre-stratified ages) in participants with Stage 3 T1D followed by open label combination therapy with either verapamil or no further treatment on a 1:1 basis in people who meet the weight requirement for initiating verapamil. The primary endpoint is the difference between mean ATG values of the 2-hr mixed meal tolerance test (MMTT)-stimulated area under the curve (AUC) C-peptide at 12 months (standard T1D trial measure) and the difference between the change in the same measure over the first 6 months. Participants will be stratified based on their ex vivo immune responder signature to allow an equal number of "responders" and "non-responders". Following each participant's completion of this 1 year trial they will enter Aim 2 and be re-randomized to received verapamil or not in an open-label 1 year extension where mechanistic endpoints will be explored related to immunophenotyping, gene expression, DNA methylation and beta cell markers including markers of beta cell stress and death as well as markers of abnormal prohormone processing. Participants must weigh ≥ 30 kg per prior to taking verapamil to participate in this arm of the trial, as per previous trials in T1D.

03

Conditions studied

  • Type 1 Diabetes
04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
4 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be >= 4 years \<= 35
  2. Must have a diagnosis of T1D for less than 100 days at randomization
  3. Willing to provide or have a parent or legal guardian provide informed consent if the subject is \<18 years of age
  4. Positive for at least one islet cell autoantibody; GAD65A, mIAA, if obtained within 10 days of the onset of insulin therapy, IA-2A, ICA, or ZnT8A
  5. Must have stimulated C-peptide levels of 0.2 pmol/ml measured during a mixed meal tolerance test (MMTT) conducted at least 21 days from diagnosis of diabetes. Randomization should occur within one month (37 days) of the MMTT.
  6. Subjects who are EBV seronegative at screening must be EBV PCR negative within 30 days of randomization and may not have had signs or symptoms of an EBV compatible illness lasting longer than 7 days within 30 days of randomization
  7. Be at least 6 weeks from last live immunization
  8. Participants are required to receive killed influenza vaccination at least 2 weeks prior to randomization when vaccine for the current or upcoming flu season is available
  9. Be willing to forgo during the treatment period and for 3 months following last dose of study drug
  10. Be willing to comply with intensive diabetes management
  11. If they meet the 30kg weight criteria at one year they will be eligible for the open-label verapamil experimental arm of the study

Exclusion criteria

Exclusion Criteria:

  1. Be immunodeficient or have chronic lymphopenia: (Leukopenia (\< 3,000 leukocytes /μL), neutropenia (\<1,500 neutrophils/μL), lymphopenia (\<800 lymphocytes/μL), or thrombocytopenia (\<100,000 /μL).
  2. Have active signs or symptoms of acute infection at the time of randomization
  3. Have evidence of prior or current tuberculosis infection as assessed by PPD, interferon gamma release assay or by history
  4. Be currently pregnant or lactating, or anticipate getting pregnant within the two year study period
  5. Require use of other agents including chronic use of systemic
  6. Have evidence of current or past , or infection
  7. Have any complicating medical issues or abnormal clinical laboratory results that may interfere with study conduct, or cause increased risk to include pre-existing cardiac disease, , sickle cell disease, neurological, or blood count abnormalities
  8. Have a history of other than skin
  9. Evidence of liver dysfunction with or ALT greater than 3 times the
  10. Evidence of renal dysfunction with creatinine greater than 1.5 times the upper limit of normal
  11. Vaccination with a live virus within the last 6 weeks
  12. Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control within prior 7 days of screening
  13. Active participation in another T1D treatment study in the previous 30 days
  14. Prior treatment with any agent to delay beta cell loss in T1D
  15. Known allergy to ATG or Verapamil
  16. Prior treatment with ATG, Verapamil or known allergy to rabbit derived products
  17. Any condition that in the investigator's opinion may adversely affect study participation or may compromise the study results
  18. Blood pressure (either systolic or diastolic) \<5th percentile for age, gender, and height on two out of three measurements at the 12-month study visit. For the adult population, a blood pressure of less than 90/60 on two out of three measurements at the 12-month study visit.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Anti-thymocyte globulin (ATG) intravenous infusion

    ATG (brand name Thymoglobulin) a polyclonal T cell antibody preparation. It will be given at low doses (0.5 mg/kg Day 1 then 2 mg/kg Day 2).

    Drug: Anti-thymocyte globulin (ATG)

  • Experimental
    verapamil extended release capsule

    Open label administration at 120, 240 or 360 mg daily based on weight and ECG findings

    Drug: verapamil extended release capsule

Interventions

  • DrugAntilymphocyte SerumStudies of Antilymphocyte SerumAntilymphocyte Serum pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    ATG (brand name Thymoglobulin) a polyclonal T cell antibody preparation. It will be given at low doses (0.5 mg/kg Day 1 then 2 mg/kg Day 2).

    Also known as: Thymoglobulin

  • DrugVerapamilStudies of VerapamilVerapamil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Open label administration at 120, 240 or 360 mg daily based on weight and ECG findings

    Also known as: Calan, Isoptin

06

What researchers measure

Primary outcomes

  1. AUC C-peptide between ATG responder and non-responder arms

    mean difference between ATG responder and non-responder arm values of the 2-hr mixed meal tolerance test (MMTT)-stimulated area under the curve (AUC) C-peptide at 12 months

    Time frame: 12 Months

  2. Change in 2-hr MMTT AUC C-peptide

    mean difference between the change in 2-hr MMTT stimulated AUC C-peptide

    Time frame: 6 months

Secondary outcomes

  1. Immune and beta cell mechanistic analyses

    To explore mechanisms of synergy between ATG received in year 1 and the addition of open-label verapamil in year 2.

    Time frame: 6, 12, 18, 24 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Haller MJ, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Miller JL, Atkinson MA, Becker DJ, Baidal D, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell W, Wilson DM, Greenbaum CJ; Type 1 Diabetes TrialNet ATG-GCSF Study Group. Low-Dose Anti-Thymocyte Globulin (ATG) Preserves beta-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. Diabetes Care. 2018 Sep;41(9):1917-1925. doi: 10.2337/dc18-0494. Epub 2018 Jul 16. PubMed 30012675 ↗
  • Foster TP, Jacobsen LM, Bruggeman B, Salmon C, Hosford J, Chen A, Cintron M, Mathews CE, Wasserfall C, Brusko MA, Brusko TM, Atkinson MA, Schatz DA, Haller MJ. Low-Dose Antithymocyte Globulin: A Pragmatic Approach to Treating Stage 2 Type 1 Diabetes. Diabetes Care. 2024 Feb 1;47(2):285-289. doi: 10.2337/dc23-1750. PubMed 38117469 ↗
  • Lin A, Mack JA, Bruggeman B, Jacobsen LM, Posgai AL, Wasserfall CH, Brusko TM, Atkinson MA, Gitelman SE, Gottlieb PA, Gurka MJ, Mathews CE, Schatz DA, Haller MJ. Low-Dose ATG/GCSF in Established Type 1 Diabetes: A Five-Year Follow-up Report. Diabetes. 2021 May;70(5):1123-1129. doi: 10.2337/db20-1103. Epub 2021 Feb 25. PubMed 33632742 ↗
  • Ovalle F, Grimes T, Xu G, Patel AJ, Grayson TB, Thielen LA, Li P, Shalev A. Verapamil and beta cell function in adults with recent-onset type 1 diabetes. Nat Med. 2018 Aug;24(8):1108-1112. doi: 10.1038/s41591-018-0089-4. Epub 2018 Jul 9. PubMed 29988125 ↗

Individual participant data

Plan to share: No — resources generated by this proposal will be made available to the general scientific community through publication in peer-reviewed journals and presentation at national/international meetings. Genomic data in the form of transcriptomic, epigenomic, and gene expression data will be generated. This proposal includes \< 60 human samples. Nonetheless, I will prepare the data for submission to appropriate public repositories. These include 1) the National Center for Biotechnology Information (NCBI, https://www.ncbi.nlm.nih.gov/) Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo) for functional genomic data, 2) Encyclopedia of DNA Elements (ENCODE) for transcriptional and epigenetic data, and 3) immuneACCESS (https://clients.adaptivebiotech.com/immuneaccess) for immune repertoire data. I will follow the standardization of these organizations to provide valuable data allowing for reproducible results following the FAIR principles (Findable, Accessible, Interoperable, Reusable).

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2028, 36 months after the start.

Of 83 non-industry phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's planned 36 months is below that.

Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2024
First posted
Jun 12, 2024
StartActual
Nov 12, 2025
Primary completionEst.
Nov 2028
CompletionEst.
Aug 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
Minimum age 6 Years→4 Years; 1 inclusion criterion edited, 1 added; 1 exclusion criterion added
What changed in the criteria
Inclusion criteria
  • EditedMust be >= 64 years <= 35
  • AddedIf they meet the 30kg weight criteria at one year they will be eligible for the open-label verapamil experimental arm of the study
Exclusion criteria
  • AddedBlood pressure (either systolic or diastolic) <5th percentile for age, gender, and height on two out of three measurements at the 12-month study visit. For the adult population, a blood pressure of less than 90/60 on two out of three measurements at the 12-month study visit.
Nov 16, 2026
Interventions
Removed Drug: Placebo. Arms removed: Placebo-ATG
Nov 16, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedAUC C-peptide between ATG responder and placebo valuesnon-responder armsTime frame: 12 Months
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Eligibility Minimum age 6 Years→4 Years; 1 inclusion criterion edited, 1 added; 1 exclusion criterion added
    What changed in the criteria
    Inclusion criteria
    • EditedMust be >= 64 years <= 35
    • AddedIf they meet the 30kg weight criteria at one year they will be eligible for the open-label verapamil experimental arm of the study
    Exclusion criteria
    • AddedBlood pressure (either systolic or diastolic) <5th percentile for age, gender, and height on two out of three measurements at the 12-month study visit. For the adult population, a blood pressure of less than 90/60 on two out of three measurements at the 12-month study visit.
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedAUC C-peptide between ATG responder and placebo valuesnon-responder armsTime frame: 12 Months
    Interventions Removed Drug: Placebo. Arms removed: Placebo-ATG
    + 2 other changes: description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06455319
Responsible party
Sponsor
First posted
Jun 12, 2024
Start date
Nov 12, 2025
Primary completion
Nov 2028 (estimated)
Completion
Aug 2030 (estimated)
Last update
Nov 16, 2026

Study contacts

Jennifer L Hosford, MPH
Contact
jennifer.hosford@peds.ufl.edu
352-294-5760
Laura M Jacobsen, MD
principal investigator · University of Florida

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Antilymphocyte Serum · Verapamil

Start the discussion